Eton Pharmaceuticals
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of Eton Pharmaceuticals generated cash of $6,815,000, which is more than the previous year. Cash used in financing activities reached the amount of -$957,000 last year. Net change in cash is therefore $5,083,000.
Cash Flow
| 2017 | -4.71M | -130K | 18.00M |
|---|---|---|---|
| 2018 | -8.14M | -236K | 21.96M |
| 2019 | -18.02M | -1.84M | 5.20M |
| 2020 | -22.34M | -50K | 31.62M |
| 2021 | -4.72M | -2.55M | 391K |
| 2022 | 4.82M | -2.78M | -134K |
| 2023 | 6.81M | -775K | -957K |
ETON Cash Flow Statement (2017 – 2023)
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|
Cash at beginning of period | 16.30M | 14.40M | 21.29M | 12.06M | 26.73M | 13.15M | 0 |
Operating activities | |||||||
Net income | -936K | -9.02M | -1.95M | -27.97M | -18.32M | -12.74M | -7.15M |
| Adjustments to reconcile net income to cash generated by operating activities: | |||||||
Depreciation and amortization | 901K | 1.77M | 462K | 651K | 447K | 63K | 13K |
Stock-based compensation expense | 3.13M | 4.21M | 3.38M | 2.57M | 1.88M | 1.85M | 2.64M |
| Deferred income tax benefit | 3.13M | 4.21M | 3.38M | 2.57M | 1.88M | 1.85M | 2.64M |
| Changes in operating assets and liabilities: | |||||||
Accounts receivable, net | -1.55M | 3.61M | -5.42M | 425K | -473K | 0 | 0 |
Inventories | -354K | -7K | 692K | -862K | -380K | 0 | 0 |
Accounts payable | 53K | -8K | -570K | 1.76M | -377K | 413K | 539K |
Cash generated by operating activities | 6.81M | 4.82M | -4.72M | -22.34M | -18.02M | -8.14M | -4.71M |
Investing activities | |||||||
Purchases Of Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Investments In Property Plant And Equipment | -775K | -2.78M | -3.25M | -50K | -1.84M | -236K | -130K |
Acquisitions Net | 0 | 0 | 700K | 0 | 0 | 0 | 0 |
Cash generated by investing activities | -775K | -2.78M | -2.55M | -50K | -1.84M | -236K | -130K |
Financing activities | |||||||
Common Stock Issued | 198K | 251K | 541K | 28.78M | 226K | 22.80M | 18.00M |
Payments for dividends | 0 | 0 | 0 | 0 | 0 | -1.04M | 0 |
Repurchases of common stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repayments of term debt | -1.15M | -385K | -150K | -2.47M | 4.75M | 0 | 0 |
Cash used in financing activities | -957K | -134K | 391K | 31.62M | 5.20M | 21.96M | 18.00M |
Net Change In Cash | 5.08M | 1.89M | -6.88M | 9.22M | -14.66M | 13.57M | 13.15M |
Cash at end of period | 21.38M | 16.30M | 14.40M | 21.29M | 12.06M | 26.73M | 13.15M |
| Data source | Data source | Data source | Data source | Data source | Data source |